CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer
cell growth and by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have
metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.